Soliciting Strategies for Developing Cell-Based Reference Materials to Advance Mesenchymal Stromal Cell Research and Clinical Translation

The mesenchymal stromal cell (MSC) field continues to rapidly progress with a number of clinical trials initiated and completed, with some reported successes in multiple clinical indications, and a growing number of companies established. The field, nevertheless, faces several challenges. Persistent issues include the definition of a MSC and comparability between MSC preparations. This is because of inherent cell heterogeneity, the absence of markers that are unique to MSCs, and the difficulty in precisely defining them by developmental origin. Differences in the properties of MSCs also depend on the site of tissue harvest, phenotypic and genotypic characteristics of the donor and the isolation, and storage and expansion methods used. These differences may be sufficient to ensure that attributes of the final MSC product could differ in potentially significant ways. Since there are currently no gold standards, we propose using a reference material to establish methods of comparability among MSC preparations. We suggest four possible "ruler scenarios" and a method for global distribution. We further suggest that critical to establishing a reference material is the need to define protocols for comparing cells. The main purpose of this article is to solicit input in establishing a consensus-based comparison. A comparative approach will be critical to all stages of translation to better clarify mechanisms of MSC actions, define an optimal cell manufacturing process, ensure best practice clinical investigations, extend the use of an MSC product for new indications, protect an MSC product from imitators, and develop uniform reimbursement policies. Importantly, a reference material may enable a consensus on a practical definition of MSCs.

[1]  A. Friedenstein,et al.  THE DEVELOPMENT OF FIBROBLAST COLONIES IN MONOLAYER CULTURES OF GUINEA‐PIG BONE MARROW AND SPLEEN CELLS , 1970, Cell and tissue kinetics.

[2]  P. Hematti,et al.  Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells. , 2008, Experimental hematology.

[3]  Bernhard M. Schuldt,et al.  A bioinformatic assay for pluripotency in human cells , 2011, Nature Methods.

[4]  Armand Keating,et al.  Mesenchymal stromal cells: new directions. , 2012, Cell stem cell.

[5]  D. Soligo,et al.  Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. , 2002, Experimental hematology.

[6]  N. Kulagina,et al.  Fibroblast precursors in normal and irradiated mouse hematopoietic organs. , 1976, Experimental hematology.

[7]  E. Miljan,et al.  Implantation of c-mycER TAM immortalized human mesencephalic-derived clonal cell lines ameliorates behavior dysfunction in a rat model of Parkinson's disease. , 2009, Stem cells and development.

[8]  P. Giannoudis,et al.  Single-platform quality control assay to quantify multipotential stromal cells in bone marrow aspirates prior to bulk manufacture or direct therapeutic use. , 2012, Cytotherapy.

[9]  B. Larson,et al.  Sox11 is expressed in early progenitor human multipotent stromal cells and decreases with extensive expansion of the cells. , 2010, Tissue engineering. Part A.

[10]  J. Shay,et al.  Hypoxia-Inducible Factor 1 Mediates Upregulation of Telomerase (hTERT) , 2004, Molecular and Cellular Biology.

[11]  R. Henschler,et al.  Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase , 2011, Leukemia.

[12]  R. Romieu-Mourez,et al.  Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing , 2011, Cytotherapy.

[13]  A. Luttun,et al.  Differentiation Potential of Human Postnatal Mesenchymal Stem Cells, Mesoangioblasts, and Multipotent Adult Progenitor Cells Reflected in Their Transcriptome and Partially Influenced by the Culture Conditions , 2011, Stem cells.

[14]  L. Sensébé,et al.  Mesenchymal stromal cells: misconceptions and evolving concepts. , 2013, Cytotherapy.

[15]  Francesco Dazzi,et al.  Mesenchymal stem cells: the fibroblasts’ new clothes? , 2009, Haematologica.

[16]  Terence R Flotte,et al.  Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. , 2010, Human gene therapy.

[17]  S. Gronthos,et al.  The STRO-1+ fraction of adult human bone marrow contains the osteogenic precursors. , 1994, Blood.

[18]  G. Sukhikh,et al.  Mesenchymal Stem Cells , 2002, Bulletin of Experimental Biology and Medicine.

[19]  Gene Kopen,et al.  Plastic adherent stromal cells from the bone marrow of commonly used strains of inbred mice: Variations in yield, growth, and differentiation , 1999, Journal of cellular biochemistry.

[20]  A. Skowera,et al.  Clinical-Grade Multipotent Adult Progenitor Cells Durably Control Pathogenic T Cell Responses in Human Models of Transplantation and Autoimmunity , 2013, The Journal of Immunology.

[21]  B. Sacchetti,et al.  Self-Renewing Osteoprogenitors in Bone Marrow Sinusoids Can Organize a Hematopoietic Microenvironment , 2007, Cell.

[22]  Peiman Hematti,et al.  Mesenchymal stromal cells and fibroblasts: a case of mistaken identity? , 2012, Cytotherapy.

[23]  K. Tarte,et al.  Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. , 2013, Cytotherapy.

[24]  Yufang Shi,et al.  Apoptotic Cells Induce Immunosuppression through Dendritic Cells: Critical Roles of IFN-γ and Nitric Oxide1 , 2008, The Journal of Immunology.

[25]  B. Lim,et al.  Molecular basis of immortalization of human mesenchymal stem cells by combination of p53 knockdown and human telomerase reverse transcriptase overexpression. , 2013, Stem cells and development.

[26]  Louis Casteilla,et al.  Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). , 2013, Cytotherapy.

[27]  Ben D. MacArthur,et al.  Mesenchymal and haematopoietic stem cells form a unique bone marrow niche , 2010, Nature.

[28]  Ulrich Göbel,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 20, 2013. For personal use , 2004 .

[29]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.